[
  {
    "ts": null,
    "headline": "Hartford Healthcare Fund Q4 2024 Commentary",
    "summary": "The Hartford Healthcare Fund (I share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=92dd3485faf0f8a524606aed0034df8cfd23fdf8f703e993912a4e84ebe7bca2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740433380,
      "headline": "Hartford Healthcare Fund Q4 2024 Commentary",
      "id": 132867176,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/200386256/image_200386256.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Hartford Healthcare Fund (I share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=92dd3485faf0f8a524606aed0034df8cfd23fdf8f703e993912a4e84ebe7bca2"
    }
  },
  {
    "ts": null,
    "headline": "Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list",
    "summary": "Drug compounders sued the U.S. Foodand Drug Administration on Monday over its decision last week toremove Novo Nordisk's weight-loss and diabetestreatments Wegovy and Ozempic from its shortage...",
    "url": "https://finnhub.io/api/news?id=91578e1b81131b1c839be5ae7ea3ba67968b118792aeb1c1601e6d862f3d467d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740413256,
      "headline": "Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list",
      "id": 132865764,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Drug compounders sued the U.S. Foodand Drug Administration on Monday over its decision last week toremove Novo Nordisk's weight-loss and diabetestreatments Wegovy and Ozempic from its shortage...",
      "url": "https://finnhub.io/api/news?id=91578e1b81131b1c839be5ae7ea3ba67968b118792aeb1c1601e6d862f3d467d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
    "summary": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
    "url": "https://finnhub.io/api/news?id=1bd4f5f8bd08de3bfa512d8c1495784973c8974a9e45da89c577c73c12083298",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740405840,
      "headline": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
      "id": 132881611,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
      "url": "https://finnhub.io/api/news?id=1bd4f5f8bd08de3bfa512d8c1495784973c8974a9e45da89c577c73c12083298"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Growth Opportunities Fund Q4 2024 Commentary",
    "summary": "The Hartford Growth Opportunities Fund (I shares) outperformed the Russell 3000 Growth Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=af84d548adb4abe5d24780886d91b4c1b3095ffd41d3c2f4009f13a6f6d44f4c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740396480,
      "headline": "Hartford Growth Opportunities Fund Q4 2024 Commentary",
      "id": 132864481,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1158571591/image_1158571591.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Hartford Growth Opportunities Fund (I shares) outperformed the Russell 3000 Growth Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=af84d548adb4abe5d24780886d91b4c1b3095ffd41d3c2f4009f13a6f6d44f4c"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Large Cap Growth Fund Q4 2024 Commentary",
    "summary": "Columbia Large Cap Growth Fund Institutional Share Class Shares returned 5.71% for Q4 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=479bbe97802f2ba4774f3161c5aba7ae93a134d6c8186f50916582477de247c0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740393000,
      "headline": "Columbia Large Cap Growth Fund Q4 2024 Commentary",
      "id": 132864077,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1044528598/image_1044528598.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Columbia Large Cap Growth Fund Institutional Share Class Shares returned 5.71% for Q4 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=479bbe97802f2ba4774f3161c5aba7ae93a134d6c8186f50916582477de247c0"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Core Equity Fund Q4 2024 Commentary",
    "summary": "Hartford Core Equity Fund (I Share) outperformed the S&P 500 Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=2079432c886a5108138347e7663cc9bcd3193224cfaf7ade8e8cca98d785fcfa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740387600,
      "headline": "Hartford Core Equity Fund Q4 2024 Commentary",
      "id": 132863595,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1854677474/image_1854677474.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hartford Core Equity Fund (I Share) outperformed the S&P 500 Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=2079432c886a5108138347e7663cc9bcd3193224cfaf7ade8e8cca98d785fcfa"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth",
    "summary": "Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See why HIMS stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=6026f21b197df0ca43b0d564289100a8eb16fba4468aa98b05a66331b2646be0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740361529,
      "headline": "Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth",
      "id": 132861275,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178836341/image_2178836341.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See why HIMS stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=6026f21b197df0ca43b0d564289100a8eb16fba4468aa98b05a66331b2646be0"
    }
  }
]